Market Struggles Weigh on Medtronic as Shares Slide
Medtronic MDT ended the last trading session at $79.99, marking a slight decline of 0.05% from the day before. The year 2024 has been challenging for investors in the Medical Products sector, mainly due to escalating geopolitical tensions, particularly around the Red Sea. These factors have led to increased freight costs and longer shipping times, negatively impacting Medtronic and its competitors, including Abbott ABT and Boston Scientific BSX, which have seen their profit margins shrink.
In the past month, Medtronic’s shares have fallen by 5.6%, which is worse than the 5% drop seen in its industry and the 0.7% decline of the S&P 500. Meanwhile, Boston Scientific and Abbott have reported smaller losses of 3.1% and 4.1%, respectively, thanks to more optimistic industry forecasts. Medtronic’s stagnant performance can be attributed to several company-specific issues.
Performance Overview for the Last Month
Image Source: Zacks Investment Research
Key Reasons for Medtronic’s Share Price Drop
Fed Indicates Fewer Rate Cuts in 2025: Investor sentiment improved recently, following the IMF’s October world economic outlook, which noted a decline in global inflation rates from 6.8% in 2023 to 5.8% in 2024, and further down to 4.3% in 2025. However, the Federal Reserve’s cautious stance on rate cuts in 2025 has dampened market outlook. On December 18, while announcing its third rate cut of 2024, the Fed hinted at future cuts, driven by concerns of rising inflation expectations.
U.S.-China Trade Issues Threaten Growth: The 2024 National Trade Estimate report highlighted ongoing U.S.-China trade tensions and their detrimental effects on American medical device companies. Medtronic generates about 7% of its operational revenue from China as of fiscal 2024, meaning continued trade difficulties could adversely affect its business performance if not resolved soon.
MDT Below Key Moving Averages
Currently, MDT shares are trading below both their 50-day and 200-day moving averages, indicating a potential continued decline in the stock’s price.
Analysis of 50 & 200-Day Moving Averages
Image Source: Zacks Investment Research
Positive Long-Term Outlook
Despite facing various industry-wide challenges, Medtronic’s solid fundamentals and strategic initiatives suggest that these current issues may be temporary.
Medtronic is working to expand its global footprint to meet growing needs for advanced medical devices. In the Cardiovascular sector, the company is increasing its market presence by launching new products in Cardiac Rhythm Management (CRM) and Structural Heart. CRM, one of its largest segments, continues to lead the market, supported by strong demand for Defibrillation Solutions and cardiac pacing therapies. In Structural Heart, Medtronic anticipates strong growth from Transcatheter aortic valve replacement applications.
Additionally, hypertension represents a substantial opportunity for MDT. The Centers for Medicare & Medicaid Services (CMS) has recently approved inpatient and outpatient payments for the Symplicity Spyral renal denervation catheter, aiding in the treatment of high blood pressure under the Medicare system.
In the MedSurg segment, Medtronic is ramping up production of the Hugo robotic-assisted surgery platform. The Surgical and Neuroscience product lines are performing well, while the Pacing division is experiencing growth due to the global uptake of its Micra leadless pacemaker. Continued innovations and efforts to broaden market reach are helping Medtronic navigate inflation and supply chain challenges.
For investors watching dividends, Medtronic’s current yield stands at 3.5%, which is better than the industry and sector averages. The company’s payout ratio is at 53%, in contrast to the industry’s 36.5%.
For comparison, Abbott’s dividend yield is 1.97%, and Boston Scientific does not offer any dividends.
Attractive Valuation
Currently, MDT stock is valued at a discount within the Medical Products sector, with a forward 12-month P/E ratio of 14.0X, significantly lower than the industry average of 20.34X.
Image Source: Zacks Investment Research
Should You Consider Investing in Medtronic?
While Medtronic has promising long-term prospects and a favorable dividend payout trend compared to its peers, the current short-term challenges are limiting the stock’s immediate performance. Investors already holding shares should maintain their positions, while new investors may want to wait for a more favorable entry point after a possible retraction in stock prices.
Zacks Names Top Semiconductor Stock
Although it’s only 1/9,000th the size of NVIDIA, which has surged over 800% since our recommendation, our new favorite semiconductor stock holds significant potential for growth.
With strong earnings and an expanding customer base, this company is set to thrive amid the soaring demand for Artificial Intelligence, Machine Learning, and Internet of Things. The global semiconductor market is expected to explode from $452 billion in 2021 to an estimated $803 billion by 2028.
See This Stock Now for Free >>
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com, click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
